Have you or a loved one developed Gastroparesis from taking Ozempic?
If you or a loved one have experienced gastrointestinal side effects after using Ozempic, which contains the active ingredient semaglutide, you may be entitled to compensation. Often, the side effect is Gastroparesis (Stomach Paralysis). This disorder slows or stops the movement of food from your stomach to your small intestine, even though there is no blockage in the stomach or intestines. Our experienced legal team is dedicated to helping individuals who have suffered from health issues related to this medication. We understand the potential challenges Ozempic poses and its association with gastrointestinal concerns, and we are here to guide you through the legal process.
Regulatory Timeline – Ozempic
Warnings
- Vomiting and Gastroparesis – lost in the shuffle.
- Gastroparesis is not in there.
- Vomiting is in there but linked to other conditions.
- More recent labeling (2023) zeroing in on vomiting and gastroparesis.
Vomiting (OZ)
“12-2017: Product label don’t disclose the issues around the Gastroparesis”
Launch Label
Instructions
Inform patients of the potential risks and benefits of OZEMPIC and of alternative modes of therapy. Inform patients about the importance of adherence to dietary instructions, regular physical activity, periodic blood glucose monitoring and A/c testing, recognition and management of hypoglycemia and hyperglycemia, and assessment for diabetes complications. Advise patients to seek medical advice promptly during periods of stress such as fever, trauma, infection, or surgery as medication requirements may change.
Advise patients that the most common side effects of OZEMPIC are nausea, vomiting, diarrhea, abdominal pain and constipation. Inform patients that nausea, vomiting and diarrhea are most common when first starting OZEMPIC, but decreases over time in the majority of patients.
Instruct patients to reread the Medication Guide each time the prescription is renewed.
Inform patients if a dose is missed, it should be administered as soon as possible within 5 days after the missed dose. If more than 5 days have passed, the missed dose should be skipped and the next dose should be administered on the regularly scheduled day. In each case, inform patients to resume their regular once weekly dosing schedule.
Manufactured by:
Novo Nordisk A/S
DK-2880 Bagsvaerd
Denmark
For information about OZEMPIC contact:
Novo Nordisk Inc.
800 Scudders Mill Road
Plainsboro, NJ 08536
1-888-693-6742
Date of Issue: December 2017
Version: 1
OZEMPIC and NovoFine ure registered trademarks of Novo Nordisk A/S.
PATENT INFORMATION: http://novonordisk-us.com/patients/products/product-patents.html
© 2017 Novo Nordisk
PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).
Rusk of Thyroid C-cell Tumors
Inform patients that semagtutide causes thyroid C-cell tumors in rodents and that the human relevance of this finding has not been determined. Counsel patients to report symptoms of thyroid tumors (e.g., a hump in the neck. hoarseness. dysphagia. or dyspnea) to them physician.
Pancreatitis
Inform patients of the potential risk for pancreatitis. Instruct patients to discontinue OZEMPIC promptly and contact their physician if pancreatitis 1s suspected (severe abdominal pain that may radiate to the back. and which may of may not be accompanied by vomiting).
Diabetic Retinopathy Complications
Inform patients to contact their physician if changes in vision are experienced during treatment with OZEMPIC.
Never Share an OZEMPIC Pen Between Patients
Advise patients that they must never share an OZEMPIC pen with another person, even if the needle is changed, because dog so caries a risk for transmission of blood-borne pathogens.
Dehydration and Renal Failure
Advise patients treated with OZEMPIC of the potential risk of dehydration due to gastrointestinal adverse reactions and take precautions to avoid fluid depletion. Inform patients of the potential risk for worsening renal function and explain the associated signs and symptoms of renal impairment, as well as the possibility of dialysis as a medical intervention if renal failure occurs.
Hypersensitivity Reactions
Inform patients to Stop taking OZEMPIC and seek medical advice promptly if symptoms of hypersensitivity reactions occur.
Pregnancy
Advise a pregnant woman of the potential nsk to a fetus. Advise women to inform their healthcare provider. if they are pregnant or intend to become pregnant.
Inform patients if a dose is missed, it should be administered as soon as possible within 5 days after the missed dose. If more than 5 days have passed. the missed dose should be skipped and the next dose should be admimustered on the regularly scheduled day. In each case. inform patients to resume them regular once weekly dosing schedule.
Manufactured by:
Novo Nordisk A/S
DK-2880 Bagsvaerd
Denmark
Novo Nordisk: STATISTICS N’ FACTS:
88 % of Novo Nordisk’s revenue generated by diabetes and obesity related products in 2022
26% Increase in Sales Worldwide between 2021 and 2022 (noted a decrease in sales of Insulin)
77% increase in Ozempic sales between 2021 and 2022
101% increase in sales of all obesity care products (Ozempic, Saxenda, and Wegovy)
Committed Legal Advocacy for Ozempic-Related Gastroparesis Claims
Our reputable law firm specializes in handling cases involving pharmaceutical-related health concerns. We understand the complexities of product liability claims and are well-prepared to advocate for your rights. If you have suffered from gastrointestinal side effects that you believe are linked to Ozempic, our legal team is committed to pursuing the compensation you deserve. Your health and well-being are our top priorities, and we will work tirelessly to ensure that responsible parties are held accountable. Contact us today for a confidential consultation and take the first step towards seeking justice.
